It took the U.S. Food and Drug Administration greater than 15 months to answer a whistleblower criticism it received about conditions at an Abbott Nutrition factory that was experiencing a nationwide shortage of infant formula, a brand new audit shows.
The Department of Labor received the e-mail and forwarded it three days later to an FDA address specifically for such complaints. But one in all several employees then in command of managing FDA inboxes “accidentally archived” the e-mail in February 2021, and it was not found until June 2022 when a reporter requested it.
The incident is one in all several that prompted the Office of the Inspector General of the Department of Health to Conclude A report released Thursday said FDA policies and procedures for addressing problems on the Abbott plant were inadequate.
While the FDA took some actions and conducted follow-up inspections, “more could have been done in advance of the Abbott infant formula recall,” the auditors wrote. The FDA needs higher policies to report the status of complaints to senior management and be certain that inspections are conducted quickly, the report concluded.
“The key is for the FDA to do a better job in the future and for the American public to have better expectations,” Deputy Inspector General Carla Lewis said in an interview.
Several infants were hospitalized and two died from a rare bacterial infection after being fed formula made at Abbott’s Michigan factory, the most important within the country. The FDA shut down the factory For several months from February 2022, and the corporate several batches recalled popular formulas corresponding to Similac, Alimentum and EleCare.
Eventually, FDA inspectors uncovered a lot of violations on the factory, including bacterial contamination, a leaky roof and lax safety protocols, however the agency was never able to ascertain a direct link between the infections and the formula.
The latest report also notes that it took 102 days for the FDA to examine the factory after receiving one other whistleblower criticism in October 2021. During that point, the agency received two complaints – one in all illness and one in all death – about infants who consumed formula from the factory. However, the formula samples didn’t contain the Cronobacter bacteria in query.
The FDA said in an announcement that it agreed with the inspector general’s conclusions. In its own 2022 report The agency confirmed that its response was slowed by delays in processing a whistleblower criticism and in factory testing samples.
“It should be noted that the OIG’s assessment represents a snapshot in time and FDA continues to make progress,” an FDA spokesperson said.
The FDA has established a “cadre of critical food investigators that will focus exclusively on inspecting and monitoring the infant formula (and other critical food) industry,” the spokesperson said. It has also begun improving tracking of paper mailings that will contain complaints, the FDA said.
Dr. Steven Abrams, a professor of pediatrics on the University of Texas at Austin, agrees with the report’s recommendations, which include that Congress should give the FDA the authority to require manufacturers to report any tests that indicate contamination in infant formula, even when the product never leaves the factory.
“As with everything else, mistakes have been made. But the government, including the FDA, is working hard to close the gaps that exist,” Abrams said. “People need to feel comfortable about the safety of powdered infant formula.”
